Jennifer Viera

Investor Relations Contact at ENANTA PHARMACEUTICALS, INC.

Health Technology

Profile

Jennifer Viera is currently the Head-Investor Relations & Communications at Enanta Pharmaceuticals, Inc. She previously worked as the Senior Director-Corporate Communications at OvaScience, Inc. and as the Investor & Media Contact at Tetraphase Pharmaceuticals, Inc.

Jennifer Viera active positions

Companies	Position	Start
ENANTA PHARMACEUTICALS, INC.	Investor Relations Contact	01/01/2023

All active positions of Jennifer Viera

Former positions of Jennifer Viera

Companies	Position	End
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Corporate Officer/Principal	-
TETRAPHASE PHARMACEUTICALS, INC.	Investor Relations Contact	-

See the detail of Jennifer Viera's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jennifer Viera's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
ENANTA PHARMACEUTICALS, INC.	Health Technology

Private companies	2
Tetraphase Pharmaceuticals, Inc. Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA.	Health Technology
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Health Technology